GSK plc

In a landmark development aimed at reshaping the future of malaria prevention, GSK plc and Bharat Biotech International Ltd have jointly announced a strategic commitment to reduce the price of the world’s first malaria vaccine for children—RTS,S—to under $5 per dose by 2028. The price cut, driven by enhanced production capacity, cost-efficient manufacturing, and minimal profit margins, aligns with pledges made to Gavi, the Vaccine Alliance, as part of its 2026–2030 replenishment phase.

In a major stride toward combating antimicrobial resistance and severe bacterial infections, Bharat Biotech has entered into a strategic partnership with British pharmaceutical giant GSK plc to co-develop a pioneering vaccine for Shigellosis. The candidate, known as altSonflex1-2-3, is among the most advanced globally and is being developed using GSK’s cutting-edge GMMA platform. Bharat Biotech will oversee Phase 3 clinical trials, regulatory progression, and commercial-scale production.